| Literature DB >> 23961369 |
Jaime Carcel-Trullols1, Cristóbal Aguilar-Gallardo, Fernando Garcia-Alcalde, Miguel Angel Pardo-Cea, Joaquin Dopazo, Ana Conesa, Carlos Simón.
Abstract
Enforced cell transdifferentiation of human cancer cells is a promising alternative to conventional chemotherapy. We previously identified albumin-associated lipid- and, more specifically, saturated fatty acid-induced transdifferentiation programs in human cancer cells (HCCLs). In this study, we further characterized the adipocyte-like cells, resulting from the transdifferentiation of human cancer cell lines MCF-7 and MALME-3M, and proposed a common mechanistic approach for these transdifferentiating programs. We showed the loss of pigmentation in MALME-3M cells treated with albumin-associated lipids, based on electron microscopic analysis, and the overexpression of perilipin 2 (PLIN2) by western blotting in MALME-3M and MCF-7 cells treated with unsaturated fatty acids. Comparing the gene expression profiles of naive melanoma MALME-3M cells and albumin-associated lipid-treated cells, based on RNA sequencing, we confirmed the transcriptional upregulation of some key adipogenic gene markers and also an alternative splicing of the adipogenic master regulator PPARG, that is probably related to the reported up regulated expression of the protein. Most importantly, these results also showed the upregulation of genes responsible for Clathrin (CLTC) and other adaptor-related proteins. An increase in CLTC expression in the transdifferentiated cells was confirmed by western blotting. Inactivation of CLTC by chlorpromazine (CHP), an inhibitor of CTLC mediated endocytosis (CME), and gene silencing by siRNAs, partially reversed the accumulation of neutral lipids observed in the transdifferentiated cells. These findings give a deeper insight into the phenotypic changes observed in HCCL to adipocyte-like transdifferentiation and point towards CME as a key pathway in distinct transdifferentiation programs. DISCLOSURES: Simon C and Aguilar-Gallardo C are co-inventors of the International Patent Application No. PCT/EP2011/004941 entitled "Methods for tumor treatment and adipogenesis differentiation".Entities:
Keywords: Adipogenic Gene Markers; Cell Transdifferentiation; Clathrin; Clathrin-mediated Endocytosis; Loss of Pigmentation; PPARG; Perilipin 2; Unsaturated Fatty Acids
Year: 2012 PMID: 23961369 PMCID: PMC3725915 DOI: 10.1186/2193-1801-1-44
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Figure 1Loss of pigmentation in albumin-associated lipid-treated MALME-3M cells. MALME-3M cells were mock-treated or treated with albumin-associated lipids for 24 hours (A). Electron Microscopy of melanosome pigmentation in MALME-3M cells mock-treated or treated with Albumin-associated lipids for 24 hours (B). The arrows indicate the dark vesicles that are hallmarks of melanosomes and disappear upon albumin-associated lipid treatment.
Figure 2PLIN2 expression is increased in the cells treated with albumin-associated lipids, petroselinic and linoleic acids. MALME-3M and MCF-7 cells were treated with albumin-associated lipids, petroselinic acid (100 μg/ml) and linoleic acid (100 μg/ml) for 96 hours. The western blot band intensity corresponding to PLIN2 was normalized to the corresponding Actin band (A) for each sample (B). The average values from densitometry analyses of three separate experiments are shown. *P <0.05 compared to each control.
Endocytosis related gene expression analysis in the MALME-3M cell line after treatment with albumin-associated lipids
| GENE SYMBOL | GENE DESCRIPTION | ENSEMBL ID | FOLD CHANGE |
|---|---|---|---|
| CLTC | clathrin, heavy chain (Hc) | ENSG00000141367 | 1.46 |
| TFRC | transferring receptor (p90, CD71) | ENSG00000072274 | 3.33 |
| AP1B1 | adaptor-related protein complex 1, beta 1 subunit | ENSG00000100280 | 1.62 |
| AP1G1 | adaptor-related protein complex 1, gamma 1 subumit | ENSG00000166747 | 1.53 |
| AP1S3 | adaptor-related protein complex 1, sigma 3 subunit | ENSG00000152056 | 2.29 |
| AP2A1 | adaptor-related protein complex 2, alpha 1 subunit | ENSG00000196961 | 1.83 |
| SYNRG | synergin gamma or AP1 gamma subunit binding protein 1 | ENSG00000006114 | 1.26 |
| AP3M1 | adaptor-related protein complex 3, mu 1 subunit | ENSG00000185009 | 1.24 |
| PICALM | phosphatidylinositol binding clathrin assembly protein | ENSG00000073921 | 1.20 |
| CLINT1 | clathrin interactor 1 | ENSG00000113282 | 2.11 |
| NECAP1 | NACAP endocytosis associated 1 | ENSG00000089818 | 1.36 |
| IGF2R | insulin-like growth factor 2 receptor | ENSG00000197081 | 2.19 |
| M6PR | mannose-6-phosphate receptor (cation dependent) | ENSG00000003056 | 1.42 |
| PIK3C2B | phosphoinositide-3-kinase, class 2, beta polypeptide | ENSG00000133056 | 1.79 |
| EEA1 | early endosome antigen 1 | ENSG00000102189 | 1.91 |
| LDLR | low density lipoprotein receptor | ENSG00000130164 | 2.01 |
| LRP1 | low-density lipoprotein receptor-related protein | ENSG00000123384 | 1.70 |
| LDLRAP1 | low density lipoprotein receptor adaptor protein | ENSG00000157978 | 1.29 |
| GO:0016197 | endosome transport | 1.06E-03 | |
| GO:0005905 | coated pit | 1.10E-03 | |
| GO:0030139 | endocytic vesicle | 1.10E-03 | |
| GO:0030131 | clathrin adaptor complex | 1.25E-03 | |
| GO:0030136 | clathrin-coated vesicle | 1.25E-03 | |
| GO:0030133 | transport vesicle | 1.69E-02 | |
| GO:0030135 | coated vessicle | 1.69E-02 | |
| GO:0030118 | clathrin coat | 2.09E-02 | |
| GO:0065002 | intracellular protein transmembrane transport | 2.12E-03 | |
| GO:0042325 | regulation of phosphorylation | 2.28E-03 | |
| GO:0006897 | endocytosis | 2.38E-02 | |
| GO:0030666 | endocytic vesicle membrane | 3.10E-03 | |
| GO:0045121 | membrane raft | 3.39E-02 | |
| GO:0005768 | endosome | 3.52E-03 | |
| GO:0032799 | low-density lipoprotein receptor metabolic process | 3.62E-03 | |
| GO:0001726 | ruffle | 5.84E-01 | |
| GO:0030117 | membrane coat | 5.84E-01 | |
(A) Fold-changes in endocytosis annotated genes. Fold changes were calculated after correcting the number of RNA-seq reads mapped to the gene in each condition by the total number of reads from the sequencing experiment for that condition. (B) Enrichment analysis of GO functional categories related to endocytosis. Adjusted p-values were obtained after Benjamini and Hochberg correction (Benjamini & [Hochberg 1995]). Significant categories (adjusted p-value <0.05) are indicated in bold.
Figure 3CLTC expression is increased in the cells treated with albumin-associated lipids and with petroselinic acid. MALME-3M and MCF-7 cells were treated with albumin-associated lipids and petroselinic acid (100 μg/ml) for 96 hours. Cells were lysed, separated in a 4–12% Bis-Tris gel and probed for western blotting with antibodies against CLTC and Actin (A). The western blot band intensity corresponding to CLTC was normalized to the corresponding Actin band for each sample (B). The average values from densitometry analyses of three separate experiments are shown. *P <0.05 compared to each control.
Figure 4The CLTC-dependent endocytosis pathway regulates LD accumulation. Nile Red quantification of neutral lipids in MALME-3M and MCF-7 cells was greatly reduced by low temperatures (A) and by CHP (B). Cells were kept at 37°C or at 4°C for 120 min. in the presence of petroselinic acid (100 μg/ml) (A). Cells were co-incubated for 120 min. with petroselinic acid (100 μg/ml) alone or CHP at a concentration of 50 μg/ml in MALME-3M cells and 100 μg/ml in MCF-7 cells (B). The accumulation of neutral lipids was quantified by Nile Red staining in both experiments. The average values from three independent analyses are shown. *P <0.05 compared to each control.
Figure 5Inhibition of CLTC levels by SiRNA affects LD biogenesis. After silencing CLTC expression, biogenesis was examined by Nile Red (C, D) quantification and Oil Red O semi-quantitative determination (E, F). Experiments were performed in MALME-3M cells (C and E) and in MCF-7 cells (D and F). Cells were transiently transfected with CONT (Control) SiRNA or with CLTC SiRNA for 72 hours prior to the addition of the vehicle 24 hours prior to cell lysation. Cell lysates were then separated in a 4-12% Bis-Tris gel and probed by western blotting with antibodies against CLTC and Actin. The experiment was repeated three times and a representative western blot is shown for MALME-3M cells (A) and for MCF-7 cells (B). For the neutral lipid determinations, after transfection, cells were treated with either the vehicle or petroselinic acid (100 μg/ml) for 24 hours prior to the testing. Nile Red (C, D) and Oil Red O and hematoxylin (E, F) staining were performed as described in Materials and Methods. Quantification was assessed using the FlowJo software. Fold induction was estimated by calculating the ratio between treated conditions (Petroselinic acid) and the untreated condition (vehicle). The average values from three independent analyses are shown. *P <0.05 compared to each control in C and D. Representative photos are shown in E and F. The length of the shown size bars is 20 μm.